Current Status of New Anticoagulants in the Management of Venous Thromboembolism by Montoya, Roberto C. & Gajra, Ajeet
Hindawi Publishing Corporation
Advances in Hematology
Volume 2012, Article ID 856341, 7 pages
doi:10.1155/2012/856341
Review Article
Current Status of New Anticoagulants in the Management of
VenousThromboembolism
Roberto C.Montoya andAjeetGajra
Division of Hematology-Oncology, Department of Medicine, SUNY Upstate Medical University, 750 E Adams St.,
Syracuse, NY 13210, USA
Correspondence should be addressed to Roberto C. Montoya, montoyar@upstate.edu
Received 8 September 2011; Revised 10 November 2011; Accepted 28 November 2011
Academic Editor: Elvira Grandone
Copyright © 2012 R. C. Montoya and A. Gajra.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated
with signiﬁcant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and
vitamin K antagonists are the most common treatment and prophylaxis, and have demonstrated their eﬃcacy in a vast number of
previous studies. Despite their broad use, these agents have important limitations that have led to the development of new drugs
in a bid to overcome the disadvantages of the old ones without decreasing their therapeutic eﬀect. These novel medications, some
approved and others in diﬀerent stages of development, include direct thrombin inhibitors like dabigatran etexilate, and direct
activated factor X inhibitors like rivaroxaban. The current paper will review the characteristics, clinical trial results, and current
and potential therapeutic uses of these new agents with a focus on the categories of direct thrombin inhibitors and activated factor
X inhibitors.
Introduction
Venous thromboembolism (VTE) is a disease that encom-
passes the diagnosis of deep vein thrombosis (DVT) and pul-
monary embolism (PE). Despite being a preventable prob-
lem, VTE has a high prevalence. Without prophylaxis, the
incidence of hospital-acquired DVT is approximately 10% to
40% among medical or general surgical patients and 40%
to 60% following major orthopedic surgery. Also, approx-
imately 10% of hospital deaths are caused by PE [1]. The
eﬀectiveness of primary thromboprophylaxis, to reduce the
frequency of DVT and PE, is supported by well-established
scientiﬁc evidence. Heparin products that include unfrac-
tionated heparin (UH), low-molecular-weight heparin
(LMWH), and vitamin K antagonists (VKA) are the most
commonly used prophylactic treatments and they have de-
monstrated good eﬃcacy and cost eﬀectiveness. While these
agents have been used for many years, each class has its
drawbacks and are far from being “ideal” anticoagulants. For
this reason, the search for new anticoagulants continues and
these eﬀorts have been concentrated on drugs focusing on
two targets: thrombin and activated factor X (FXa).
These novel agents, currently approved or under evalua-
tion for management of VTE, act directly on the active sites
of thrombin or FXa and they include the direct thrombin
inhibitor (DTI) Dabigatran Etexilate and the direct FXa
inhibitors:rivaroxaban,apixaban,edoxaban,andbetrixaban.
1.DirectThrombin Inhibitors
DTIs are agents that neutralize thrombin directly by binding
to its active catalytic site and blocking its interactions with
its substrates. Thrombin plays a central role in the clotting
process. As a point of convergence of the two pathways of the
coagulationcascade,thrombinconvertssolubleﬁbrinogento
ﬁbrin and activates factors V, VIII, and XI which generate
more thrombin. It also stimulates platelets and stabilizes the
clot by activating factor XIII which favors the formation
of cross-linked bonds among the ﬁbrin molecules [2].
DTIs include the parenteral drugs argatroban, bivalirudin,2 Advances in Hematology
hirudin, and the only oral DTI available dabigatran etexilate,
which has been developed most recently.
1.1. Dabigatran Etexilate. Dabigatran etexilate (DE) is an
orally administrated, speciﬁc, and potent reversible throm-
bin inhibitor. It is a prodrug that is rapidly transformed into
its active metabolite dabigatran by a mechanism indepen-
dent of the CYP enzymes and other oxidoreductases. DE
reaches maximal plasma concentrations within two hours of
administration [3] or within four hours if it is given with
food. This variability has no ﬁnal eﬀect in the action of
the drug [4]. Dabigatran etexilate exhibits linear pharma-
cokinetic characteristics as reported in a previous study
in healthy volunteers and has a percentage of binding to
plasma proteins of about 35%. Dabigatran clearance is
predominantly renal, with 80% excreted unchanged in the
urine and for this reason needs a dose adjustment when
administered to subjects with a creatinine clearance <50mL/
min [4]. DE prolongs in a dose-dependent fashion some
coagulation tests, including activated partial thromboplastin
time (aPTT), thrombin time, and ecarin clotting time.
Although aPTT correlates with plasma concentration time
proﬁleofdabigatran,thistestisnotsuitableforprecisequan-
tiﬁcation of its anticoagulant eﬀect. On the other side, the
eﬀect of dabigatran on the prothrombin time (PT) is mini-
mal at therapeutic doses [5]. Currently, there is no antidote
to reverse the antithrombotic eﬀect of dabigatran; however,
factor VIIa is a potential candidate since it has shown its
ability to reverse the prolonged bleeding time in rats treated
with high doses of dabigatran [4].
1.1.1. Clinical Trials of Dabigatran in VTE. In 2008, DE
was approved in Europe as a primary prevention of venous
thromboembolic events in adult patients who have under-
gone elective total hip replacement or total knee replacement
surgery. In October 2010, DE was FDA approved to reduce
the risk of stroke and systemic embolism in patients with
nonvalvular atrial ﬁbrillation. Currently DE is not indicated
in the USA for any VTE event; however there are ongoing
clinical trials evaluating this potential indication and more,
under the REVOLUTION trial program which encompasses
all the studies described below.
Primary Prevention Trials. ( a )R E - M O D E Li sap h a s eI I I
clinicaltrial,conductedmainlyinEurope,thatcompareden-
oxaparin 40mg SQ once daily (ﬁrst dose given in the evening
before surgery) with DE 150mg and 220mg once daily
(started 4 hours post operatively), for prevention of VTE
after an elective total knee replacement (TKR). The duration
oftreatmentwas6–10days.TheincidenceofVTEwas36.4%
and 40.5% for 220mg and 150mg doses, respectively, and
37.7% for enoxaparin. The safety proﬁle was similar for
the three groups. These results showed that both doses of
dabigatran were noninferior to enoxaparin [6].
(b) RENOVATE is a phase III clinical trial, conducted
mainly in Europe, that compared enoxaparin 40mg SQ once
daily (ﬁrst dose given in the evening before surgery) with DE
150mg and 220mg once daily, for the prevention of VTE
after an elective total hip replacement (THR). The duration
of the treatment was 28–35 days. The incidence of VTE was
6% and 8.6% for 220mg and 150mg doses, respectively,
and 6.7% for enoxaparin. The incidence of major bleeding
was not signiﬁcantly diﬀerent among the three groups. The
results showed that either dose of DE was noninferior to
enoxaparin [7].
(c) RENOVATE II is a phase III clinical trial that com-
pared enoxaparin 40mg SQ once daily (ﬁrst dose in the
evening before surgery) with DE 220mg once daily (starting
1–4 hours after surgery) for the prevention of VTE after
THR, during a period of treatment of 28–35 days. RENO-
VATEIIissimilartoRENOVATEandaimstofurtherevaluate
the eﬃcacy and safety of DE 220mg dose in a more diverse
population, including patients from North America. The
results showed that DE was as eﬀective as enoxaparin (7.7%
versus 8.8% with a P<0.0001 for the pre-speciﬁed non-in-
feriority margin) for preventing VTE and death from all
causes and superior to enoxaparin for reducing the risk of
major VTE (proximal DVT and/or PE). The incidence of
major bleeding and adverse eﬀects was similar between both
groups [8].
(d) REMOBILIZE is a phase III study, conducted mainly
in USA and Canada, that compared enoxaparin 30mg SQ
twice daily (starting 12–24h post surgery) with DE 150mg
and 220mg once daily, for prevention of VTE after an
electiveTKR.Thedurationoftreatmentwas12–15days.The
incidence of VTE was 31.1% (P = 0.02 versus enoxaparin)
and 33.7% (P<0.001 versus enoxaparin) for 220mg and
150mg doses, respectively, and 25.3% for enoxaparin. This
trial demonstrated that dabigatran was inferior to enoxapa-
rin; however the safety proﬁle was equivalent [9].
Treatment Trials. (a) RECOVER is a phase III clinical trial
that evaluated the use of DE for 6-month treatment of acute
symptomatic VTE, as a replacement for VKAs. It compared
dabigatran 150mg twice daily with dose-adjusted warfarin
to achieve an INR of 2-3 preceded by initial treatment for 5–
10 days with parenteral anticoagulation. The results showed
that dabigatran was noninferior to warfarin (2.4% versus
2.1% with a P<0.001) in preventing recurrent VTE; major
bleeding events were comparable between both drugs and
for any bleeding events dabigatran showed a signiﬁcant 29%
reduction (P = 0.0002) in comparison to warfarin [10].
(b) RECOVER 2 is a currently ongoing clinical trial sim-
ilar to RECOVER. It evaluates DE 150mg twice daily com-
pared to warfarin (INR 2.0-3.0) for 6-month treatment of
acute symptomatic VTE, after initial treatment (5–10 days)
with a parenteral anticoagulant. This trial aims to demon-
strate the safety and eﬃcacy of DE for the long-term treat-
ment and secondary prevention of VTE [11].
(c) REMEDY is a phase III clinical trial designed to
measure the eﬃcacy and safety of DE as a treatment of VTE
for an extended period of time. In this study, patients were
randomized to receive DE 150mg BID, administered orally
or warfarin (INR 2-3) for 6 to 36 months, after being treated
with standard doses of an approved anticoagulant for 3 to 12
months for conﬁrmed acute symptomatic VTE. The results
showed that DE was as eﬀective as warfarin (1.8% versus
1.3% with a P = 0.03) to prevent recurrent VTE during theAdvances in Hematology 3
extended period of treatment and also was associated with
a reduced risk for bleeding in comparison to warfarin. On
the other hand, there was a signiﬁcant increased incidence of
acute coronary events in the group that received DE (0.9%
versus 0.2% with a P = 0.02) [12].
(d) RESONATE is a phase III clinical trial that, like
REMEDY, evaluates the use of dabigatran as treatment of
VTE for an extended period of time. In this trial, DE 150mg
BIDwascomparedto placebo in thelong-term prevention of
VTE in patients who completed 6–18 months of treatment
with a vitamin K antagonist. After an intervention period of
6 months, recurrent VTE occurred in 0.4% and 5.6% of pa-
tients treated with DE and placebo, respectively, which con-
stitutes a 92% relative risk reduction for recurrent VTE.
Clinically, relevant bleeding occurred more frequently in the
group treated with DE (5.3% versus 1.8% with a P = 0.001);
however there was not signiﬁcant diﬀerence in the incidence
of major bleeding between both groups [13].
2.DirectActivatedFactorXInhibitors
Activated factor X in interaction with activated factor V is
responsible for the conversion of prothrombin to thrombin.
The capacity of one molecule of FXa to generate 1000
molecules of thrombin [14] is well-exploited by the direct
FXa inhibitors to lessen the production of thrombin which is
responsible of converting ﬁbrinogen to ﬁbrin and activating
platelets and factors V, VIII, and XI. The ﬁnal eﬀect of the
decreased thrombin levels is the interruption of the clot
formation. In general, direct FXa inhibitors have a broad
therapeutic window, low patient variability, and minimal
drug or food interactions. For these reasons, like dabigatran,
they don’t need routine laboratory monitoring [15].
The agents in this class that are furthest along in clini-
cal testing include rivaroxaban, apixaban, edoxaban, and be-
trixaban.
2.1. Rivaroxaban. Rivaroxaban is a direct FXa inhibitor,
already approved in Europe for the prevention of VTE after
THR and TKR. Rivaroxaban is a very speciﬁc inhibitor
of the FXa and, in contrast to the indirect FXa inhibitor
fondaparinux, it is able to inactivate free and clot-associated
F X aa sw e l la sp r o t h r o m b i n a s ea c t i v i t y .R i v a r o x a b a ni s
administered orally once a day, has a bioavailability of about
80%[16],andafterbeingrapidlyabsorbedreachestheCmax
2–4 hours after. In plasma, >90% of rivaroxaban is found
bound to plasma protein and has half life of up to 12-13
hours in healthy elderly subjects [17]. One-third of the drug
is eliminated unchanged in the urine and the other two-
thirds are metabolized in the liver via CYP3A4, CYP2C8, and
CYP-independent mechanisms with part of the metabolites
excreted in the feces and other part eliminated in the
urine. Due to its mechanisms of elimination, rivaroxaban
is contraindicated in patients with a CLCr <30mL/min and
should be administrated with caution in patients with renal
and hepatic insuﬃciency. The use of rivaroxaban in con-
junction with azoles, ritonavir, and other potent CYP3A4
and P-gp inhibitors could interfere with its metabolism and
should be avoided. Rivaroxaban dose-dependent inhibition
of the FXa prolongs the PT and APTT. This eﬀect on both
tests is short lived only and not appropriate to monitor the
drug activity. PT is prolonged longer if rivaroxaban is co
administrated with food [18].
2.1.1. Clinical Trials of Rivaroxaban in VTE. Rivaroxaban
was approved in Europe and many other countries based on
the results of the RECORD (Regulation of Coagulation in
Orthopedic surgery to prevent DVT and PE) phase III clini-
cal trial program, which enrolled more than 12500 patients.
Other studies have been developed also for prophylaxis and
treatment of VTE.
PrimaryPreventionTrials. (a)RECORD1comparedrivarox-
aban 10mg daily, 6–8h post elective THR versus enoxa-
p a r i n4 0 m gd a i l y ,1 2 hp r e o p e r a t i v e l y .T h ed u r a t i o no f
the treatment was 34 days. Rivaroxaban was signiﬁcantly
superior to enoxaparin for the prevention of VTE and all-
cause mortality (1.1% versus 3.7%, P<0.001) without a
signiﬁcant diﬀerence in the rates of major bleeding or clini-
cally relevant non-major bleeding [19].
(b) RECORD2 compared rivaroxaban 10mg daily, 6–8h
after elective THR, versus enoxaparin 40mg daily, started
12h preoperatively. The duration of treatment was 31-to-
39-day course of rivaroxaban versus 10-to-14-day course of
enoxaparinfollowedby21to25daysofplacebo.Rivaroxaban
demonstrated superiority over enoxaparin for the primary
outcome of total VTE and all-cause mortality (2.0% versus
9.3%, P<0.0001). There was no signiﬁcant diﬀerence in the
rates of bleeding between both treatments [20].
(c) RECORD3 compared rivaroxaban 10mg daily, 6–8
hours after TKR, with enoxaparin 40mg daily, started 12h
preoperatively, for 10 to 14 days (short-term prophylaxis).
This study demonstrated that rivaroxaban was superior to
enoxaparin for the prevention of a composite of VTE and
all-cause mortality (9.6% versus 18.9%, P<0.001). There
was no signiﬁcant diﬀerence in the rates of bleeding between
both treatments [21].
(d) RECORD4 compared the eﬃcacy and safety of
rivaroxaban 10mg PO daily, 6–8 hours after elective TKR
with enoxaparin 30mg SQ BID, started 12h preoperatively.
The duration of treatment was 10–14 days. The results de-
monstrated signiﬁcant superiority for rivaroxaban over en-
oxaparin for the primary eﬃcacy endpoint, a composite of
total VTE and all-cause mortality (6.9% versus 10.1%, P =
0.0118). There was no signiﬁcant diﬀerence in the rate of
major bleeding between both regimens [22].
(e) MAGELLAN is a phase III clinical trial that compared
the eﬃcacy of rivaroxaban 10mg PO daily for 35 days versus
the eﬃcacy of standard 10-day treatment with enoxaparin
40mgSQdailytopreventVTEinacutelyill-medicalpatients.
Participants had an average age of 71 years and one or more
acute medical conditions, including active cancer, infec-
tious diseases, heart failure, inﬂammatory/rheumatic dis-
eases,andsoforth.Fortheprimaryeﬃcacyendpoint,acom-
posite of VTE, and death, at day 10 results showed that
rivaroxaban was noninferior to enoxaparin (2.7% versus
2.7% with a P = 0.0025 for non-inferiority). At day 35, riv-
aroxabanwassuperiortoenoxaparin(4.4%versus5.7%with4 Advances in Hematology
a P = 0.02). Bleeding rates at both 10 and 35 days were
higher with rivaroxaban and because of this the net clinical
beneﬁt (combination of the eﬃcacy and bleeding endpoints)
favored enoxaparin. Since patients in Magellan constituted
a heterogeneous group aﬀected by diﬀerent diseases, a sub-
group analysis is currently ongoing to identify patients who
could be associated with a net clinical beneﬁt [23].
Treatment Trials. (a) EINSTEIN-DVT EVALUATION is a
phase III clinical trial comparing rivaroxaban, 15mg PO
BID for 3 weeks followed by 20mg daily, versus enoxaparin
followed by VKA, for 3 to 12 months, in patients with acute
symptomatic DVT (no PE). The results showed that rivaro-
xaban had noninferior eﬃcacy with respect to the primary
outcome that was the prevention of symptomatic recurrent
DVT (2.1% versus 3.0%, P<0.001). The rate of bleeding
was similar between both groups [24].
(b) EINSTEIN PE is a phase III clinical trial, completed
but not published yet, that compares rivaroxaban 15mg BID
for 3 weeks followed by 20mg daily to enoxaparin 40mg SQ
BID for at least 5 days, in combination with VKA (INR 2-3)
in the treatment of patients with acute symptomatic PE with
or without symptomatic DVT. The primary endpoint is the
composite of recurrent DVT and/or PE occurring during the
3-, 6-, and 12-month study treatment periods [25].
(c) EINSTEIN-EXTENSION study is a phase III clinical
trial designed to assess the eﬃcacy and safety of rivaroxaban
20mg daily for 6 to 12 months, versus placebo in patients
who had completed 6 to 12 months of anticoagulant treat-
ment for their acute episode of VTE. The incidence of VTE
was 1.3% versus 7.1% for rivaroxaban and placebo, re-
spectively (P<0.001). The results demonstrated that riva-
roxaban was associated to an 82% relative risk reduction in
the recurrence of VTE in this group of patients. The rate
of bleeding for the rivaroxaban group was low and non-
statistically signiﬁcant [26].
2.2. Apixaban. Apixaban is another oral, potent, reversible,
and direct FXa inhibitor that has been tested for VTE treat-
ment and prophylaxis. It is a very selective drug and like
rivaroxaban can inhibit free FXa as well as prothrombinase
activity. Apixaban has a high oral bioavailability and after
a rapid oral absorption in the stomach and small intestine,
reaches a Cmax approximately 1–3 hours after administra-
tion. Its half-life is 8–15 hours and about 87% is bound to
plasma proteins [27]. Apixaban has a multimodal mecha-
nism of elimination. Most of the drug is excreted in the
feces, other part via CYP3A4-dependent mechanisms in the
liver, and one-fourth of the drug is eliminated in the urine
[27]. For this reason apixaban probably could be safely
used in patients with renal and hepatic insuﬃciency; but
like rivaroxaban, its concomitant use with potent CYP3A4
inhibitorslikeketoconazoleandritonavir,shouldbeavoided.
The PT and aPTT are prolonged by the use of apixaban
in a concentration-dependent fashion. However; because at
therapeutic concentrations the impact of apixaban on the PT
and aPTT is minimal, these tests are not sensitive enough for
themonitoringofthedrug[28].Ingeneral,ifeverneeded,an
FXa inhibition assay is the best way to monitor the activity of
apixaban.
2.2.1. Clinical Trials of Apixaban in VTE. Apixaban is in the
process of approval in Europe for prophylaxis after major
orthopedic surgery. The ADVANCE 1, 2, and 3 trials are the
studies presented to support this indication. Other trials to
evaluate apixaban for the prevention of VTE in patients hos-
pitalized or with metastatic cancer are also ongoing.
Primary Prevention Trials. (a) ADVANCE-1 is a phase III
study that compared apixaban 2.5mg PO BID with enoxa-
parin 30mg SQ BID for prevention of VTE after TKR. Both
drugs were started 12–24h after operation and the dura-
tion of treatment was 10–14 days. The results showed that
apixaban did not meet the prespeciﬁed statistical criteria for
non-inferiority(9.0%versus8.8%),butitsusewasassociated
with lower rates of clinically relevant bleeding and it had a
similar adverse-event proﬁle [29].
(b)ADVANCE-2isaphaseIIIclinicaltrialthatcompared
apixaban 2.5mg PO BID (12–24h postoperatively) with
enoxaparin 40mg daily (started 12h preoperatively) for pre-
vention of VTE after TKR. The results showed that apixaban
hadnoninferioreﬃcacywithrespecttotheprimaryoutcome
that was a composite of total VTE plus all-cause mortality
(15% versus 24%, P<0.0001). Further, apixaban was as-
sociated with a similar risk of bleeding [30].
(c) ADVANCE-3 is a phase III clinical trial comparing
apixaban 2.5mg PO BID (12–24h postoperatively) with
enoxaparin 40mg daily (12h before surgery) for throm-
boprophylaxis after THR. The primary eﬃcacy outcome,
a composite of VTE plus all-cause mortality, occurred in
1.4% of the patients in the apixaban group and in 3.9%
of the patients in the enoxaparin group (P<0.0001 for
bothnoninferiorityandsuperiority).Theratesofbleedingin
both groups were similar. It was concluded that among pa-
tients undergoing hip replacement, thromboprophylaxis
with apixaban, as compared with enoxaparin, was associated
with lower rates of VTE, without increased bleeding [31].
(d) ADOPT is a phase III clinical trial, completed but not
published yet, designed to assess the eﬃcacy and safety of
apixaban,2.5gmgPOBIDversusenoxaparin40mgSQdaily
for prophylaxis of VTE in acutely ill medical subjects during
and following hospitalization. The primary eﬃcacy outcome
is a composite of VTE and VTE-related death during 30-day
treatment [32].
(e) ADVOCATE is a phase II clinical trial, completed
but not published yet, designed to know the eﬀectiveness of
apixaban as anticoagulant therapy in patients with advanced
or metastatic cancer. Patients will be randomized to receive
5mg daily of apixaban or placebo during 12 weeks. The pri-
mary outcome is the occurrence of either a major bleeding
(fatal or nonfatal) event or a clinically relevant non-major
bleeding event during the treatment period. The secondary
outcome is symptoms compatible with VTE [33].
Treatment Trials. (a) BOTTICELLI is a phase II clinical
trial designed to assess eﬃcacy and safety of 3 diﬀerent
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and 20mg once daily versus conventional treatment with
low-molecular-weight heparin or fondaparinux and vita-
min K antagonist in the treatment of subjects with acute
symptomatic DVT. The duration of the treatment was
three months and the primary eﬃcacy outcome was a
composite of symptomatic recurrent VTE and deterioration
of thrombotic burden. This study concluded that apixaban
canbegivenasthesoletreatmentforDVTinaﬁxeddoseand
warranted further evaluation of apixaban in phase III studies
(AMPLIFY and AMPLIFY-EXT) [34].
(b) AMPLIFY is a phase III study, currently recruiting
participants, designed to assess the eﬃcacy and safety of
apixaban for the treatment of DVT or PE. It will compare
apixaban 10mg BID for one week followed by 5mg bid
for six months with enoxaparin 1mg/kg BID followed by
warfarin (INR 2-3) for 6 months. The primary outcome is
VTE recurrence or death during the study treatment [35].
(c) AMPLIFY-EXT is a phase III study, currently recruit-
ing participants, designed to assess the eﬃcacy and safety
of apixaban for extended treatment of DVT or PE. After
receiving 6–12 months of treatment for DVT/PE, patients
recruitedinthisstudywillberandomizedtoreceiveapixaban
2.5mg BID or apixaban 5mg BID or placebo BID for up to
12months.TheprimaryoutcomeisVTErecurrenceordeath
during the study treatment [36].
2.3. Edoxaban. Edoxaban is another orally active, reversible
and speciﬁc inhibitor of the active site of FXa, both free
of and within the prothrombinase complex. It has a bio-
availability of >50% and after a rapid absorption, in healthy
volunteers, it reaches a peak plasma level within 1.5 hours
and retains its antithrombotic eﬀect for up to 5 hours after
dosing [37]. Edoxaban is eliminated through multiple path-
ways but predominantly via renal route, so it should be used
with caution in patients with renal insuﬃciency. It has an
elimination half-life of 9–11 hours [37]. Edoxaban is meta-
bolized by the P-gp system so its dosage needs to be reduced
if is used concomitantly with potent P-gp inhibitors like
verapamil and quinidine [37]. Edoxaban prolongs the PT
and aPTT in a concentration-dependent fashion, at least in
vitro studies [4].
2.3.1. Clinical Trials of Edoxaban in VTE. Edoxaban does not
have any indication yet, however; the ﬁrst trials in Japan have
shown that it could be a potential alternative to enoxaparin
for prevention of DVT after major orthopedic surgery.
Primary Prevention Trials. (a) Fuji et al. [38]i nap h a s eI I
study evaluated the eﬃcacy and safety of edoxaban for the
prevention of VTE in patients undergoing TKR. Patients
were randomized to receive edoxaban 5, 15, 30, or 60mg
once daily or placebo for 11–14 days. The incidence of VTE
was 29.5%, 26.1%, 12.5%, and 9.1% in the edoxaban 5-,
15-, 30-, and 60-mg treatment groups versus 48.3% in the
placebo group. The incidence of bleeding was similar across
all the groups. It was concluded that edoxaban demon-
strated signiﬁcant dose-dependent reductions in VTE in
patients undergoing TKA with a bleeding incidence similar
to placebo.
( b )R a s k o be ta l .[ 39]: it is a phase II study designed to
evaluatetheeﬃcacyandsafetyofdiﬀerent doses of edoxaban
for the prevention of VTE in patients undergoing elective
THR. Patients were randomized to oral edoxaban 15, 30, 60,
or 90mg once daily or dalteparin SQ once daily (initial dose
2,500IU,subsequentdoses5,000IU).Bothdrugswerebegun
6–8 hours postoperatively and continued for 7–10 days. The
primary eﬃcacy endpoint was the incidence of total VTE.
The incidences of VTE were 28.2%, 21.2%, 15.2%, and
10.6% in patients receiving edoxaban 15, 30, 60, and 90mg,
respectively, compared with 43.8% in the dalteparin group
(P<0.005). The incidence of clinically relevant bleeding was
low and similar across the groups. It was found that there
was a statistically signiﬁcant (P<0.001) dose-response for
eﬃcacy across the edoxaban dose groups for VTE.
(c) STARS J-V is a phase III trial that evaluated the
eﬃcacyandsafetyofedoxabancomparedwithenoxaparinin
patients undergoing THR in Japan. Patients received either
30mg PO once daily of edoxaban or enoxaparin SQ 20mg
twice daily for 11 to 14 days. The primary eﬃcacy endpoint
of the trial was the incidence of PE and DVT. DVT occurred
in 2.4% of patients receiving edoxaban compared with 6.9%
in the enoxaparin group (P = 0.016). There were no PE
events observed in either treatment group. There was no
statistically signiﬁcant diﬀerence in bleeding episodes. It
wasconcludedthatedoxabandemonstratedsuperioreﬃcacy
compared with enoxaparin in preventing VTE after THR
[40].
(d) STARS E-3 is a phase III trial that compared edo-
xaban 30mg PO daily with enoxaparin 20mg SQ BID for
prevention of VTE in patients undergoing TKR in Japan and
Taiwan.Thedurationofthetreatmentwas11to14days.The
primary eﬃcacy endpoint of the trial was the incidence of PE
and DVT. DVT occurred in 7.4% of patients receiving edox-
aban and 13.9% of patients who received enoxaparin (P =
0.01).NoPEwasobservedinanytreatmentgroup.Therewas
no statistically signiﬁcant diﬀerence in the rates of bleeding
(P = 0.1 3 ) .I tw a sc o n c l u d e dt h a tE d o x a b a nw a ss u p e r -
ior to enoxaparin in preventing VTE after TKR [41].
Treatment Trial. (a) The Edoxaban Hokusai-VTE study is
a phase III clinical trial, currently recruiting participants,
designed to evaluate the eﬃcacy and safety of (LMW) hep-
arin/edoxaban versus (LMW) heparin/warfarin in subjects
with symptomatic DVT and/or PE. The primary outcome
is symptomatic recurrent VTE for 12 months from time of
randomization [42].
2.4. Betrixaban. Betrixaban is an oral, reversible, and com-
petitive direct FXa inhibitor. Like apixaban and rivaroxaban,
betrixaban is a very speciﬁc inhibitor of the FXa, both free
and bound in the prothrombinase complex [43]. In animal
models, betrixaban has a bioavailability of 49% [44]. Its
pharmacodynamichalf-lifeis20hoursandallowsanoptimal
therapeutic range using one daily dose regimen. Elimination
is mostly by biliary excretion with minimal renal clearance,
whichwould allow its usein patients with renal insuﬃciency,
without a requirement for dose adjustment. Because of
its independence with major CYP P450 enzyme pathways,6 Advances in Hematology
betrixaban has a minimal potential for drug interactions
[43].
BetrixabancausesaveryminimalprolongationofthePT,
aPTT, and the anti-FXa activity [4].
2.4.1. Clinical Trials of Betrixaban on VTE. EXPERT is a
phase II clinical trial conducted in the US and Canada that
randomized 215 patients undergoing elective TKR to receive
betrixaban 15mg or 40mg PO BID (starting 6–8 hours after
surgery) or enoxaparin 30mg SQ BID (starting 12 to 24
hours after surgery), for 10–14 days, in order to prevent
VTE. The primary eﬃcacy outcome was the incidence of
VTE from day 10 to 14. VTE occurred in 20% and 15% of
patients receiving betrixaban 15mg and 40mg respectively.
In the enoxaparin group, 10% of the patients presented VTE.
No bleeds were reported for betrixaban 15mg, two clinically
signiﬁcant nonmajor bleeds (2.4%) with betrixaban 40mg,
and one major (2.3%) and two clinically signiﬁcant non-
major (4.6%) bleeds with enoxaparin. The conclusion was
that betrixaban demonstrated antithrombotic activity and
appearedwelltolerated.Furtherstudiesareexpectedtocome
based on the results of the EXPERT trial [43].
Conclusion
Many new anticoagulants are being currently evaluated for
prevention and treatment of VTE. Based on the initial results
as outlined above, these agents oﬀer a great promise to be
potential substitutes for the current heparin products and
VKAs. Also oral route, ease of use, lack of need for routine
monitoring, minimal food and drug interactions, and an
acceptable safety proﬁle make them attractive. However, they
are more expensive and this has raised some questions about
the cost eﬀectiveness of these agents. Another concern is the
lack of eﬀective antidotes for quick and consistent reversal of
anticoagulant eﬀect. As more data emerges, these new agents
will ﬁnd wider applications; although, they are not likely
to universally replace heparins and VKAs in the immediate
future until the cost and reversal issues are better addressed.
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